ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today ...
ProQR Therapeutics is advancing its Axiomer ADAR-mediated RNA editing pipeline, aiming to file a Clinical Trial Application for its lead program AX-0810, targeting NTCP for cholestatic diseases, by Q2 ...
Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks ProQR ( (PRQR)) just unveiled an ...
LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (PRQR). (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its ...
News-Medical.Net on MSN
Study explores how reversible RNA editing could transform future cardiovascular medicine
By Hugo Francisco de Souza Emerging research suggests reversible RNA editing mechanisms may influence heart disease biology while opening new avenues for biomarkers and next-generation cardiovascular ...
Adenosine deaminase acting on RNA (ADAR) is the enzyme responsible for adenosine-to-inosine (A-to-I) RNA editing, a process essential for regulating how cells respond to double-stranded RNA. ADAR1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results